© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
August 03, 2022
According to the company, the clinical trial is reviewing EYP-1901, an investigational sustained delivery anti-vascular endothelial growth factor (anti-VEGF) treatment for wet age-related macular degeneration (wet AMD).
August 03, 2022
Retina indications for which ranibizumab-eqrn is interchangeable include neovascular (wet) age-related macular degeneration; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy, and myopic choroidal neovascularization.
August 01, 2022
The doctors will join the Cataract and Primary Eye Care, Glaucoma, and Retina Services.
July 28, 2022
Positive results from recent pre-clinical studies support the potential of long-acting PASylated nomacopan to advance toward IND/IMPD for clinical trials in geographic atrophy (GA) in dry age-related macular degeneration (dAMD), a disease with no approved treatments.
July 26, 2022
According to the company, the study assesses the safety and tolerability of a single dose of CLS-AX administered to patients diagnosed with wet AMD by suprachoroidal injection.
July 22, 2022
LBS-008 is the company’s orally administered tablet for the treatment of Stargardt disease. There are currently no FDA approved treatments for Stargardt disease or dry AMD.
July 21, 2022
A team of scientists, led by Andrzej Foik, PhD, of the International Center for Translational Eye Research in Poland, is working on new therapies that may slow vision loss in patients diagnosed with retinal degeneration.
July 20, 2022
Eyes of mice lacking protective protein show signs similar to age-related macular degeneration.
July 20, 2022
The ASRS See for a Lifetime See a Retina Specialist initiative will spotlight early detection and outline the importance of seeing a retina specialist.
July 19, 2022
According to the company, pegcetacoplan is an investigational, targeted C3 therapy for the treatment of geographic atrophy secondary to age-related macular degeneration.